TAS-102 improved overall survival compared with placebo in previously treated Asian patients with metastatic colorectal cancer (mCRC).
John L. Marshall, MD, recaps some of the biggest CRC advancements of 2017, and explains what those successes mean for the treatment paradigm moving forward.
Nancy E. Kemeny, MD, discusses the combination of pump and systemic therapy as a liver-directed treatment option for patients with metastatic colorectal cancer.
Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.
William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.
Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.
Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.
Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.
A. David McCollum, MD, discusses the optimal management of CRC in the first-line setting and the ongoing research with checkpoint inhibitors designed to benefit larger groups of patients.
Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.